Increase In Lung Cancer Incidence Fueling The Growth Of The Market Due To Rising Air Pollution And Genetic Targeted Therapies: Powering Innovation and Expansion in the Global Ensartinib Market by 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Ensartinib Market Through 2025?
In the past few years, the market size for ensartinib has experienced swift growth. Projecting this forward, the market is anticipated to expand from a value of $0.97 billion in 2024 to $1.09 billion in 2025, marking a compound annual growth rate (CAGR) of 11.4%. Factors that have contributed to this historical growth include favorable reimbursement policies, an increase in coverage by payors for specific lung cancer treatments, the extension of initiatives for early diagnosis, enhanced understanding of the advantages of targeted therapy among patients and medical professionals, and a rising focus on personalized medicine.

What's the Projected Size of the Global Ensartinib Market by 2029?
We anticipate a significant expansion in the ensartinib market in the coming years, reaching $1.65 billion in 2029 with a compound annual growth rate (CAGR) of 11.0%. The predicted growth can be credited to factors like consistent expansion in biomarker screening rates, rising instances of non-small cell lung cancer, heightened demand for specific cancer therapies, the increasing demand for outcome-based frameworks, and an enhanced emphasis on patient convenience. The anticipated trends include evolution in diagnostic methods, the incorporation of artificial intelligence in trial matching, strategic alliances with research bodies and healthcare providers, introduction of combination treatments, and increased funding in research and development.

View the full report here:
https://www.thebusinessresearchcompany.com/report/ensartinib-global-market-report

Top Growth Drivers in the Ensartinib Industry: What's Accelerating the Market?
The ensartinib market is expected to boom, propelled by the rising cases of lung cancer. Frequently, lung cancer results from the growth of abnormal cells in the lungs that grow uncontrolled, often developing tumours that disrupt normal breathing and may spread to other body parts. The prevalence of lung cancer is on the rise due to extensive exposure to air pollution, particularly fine particulate matter which harms lung tissue over time. Ensartinib plays a pivotal role in lung cancer treatment by halting the irregular activity of the ALK gene, thereby controlling tumour growth in patients suffering from ALK-positive non-small cell lung cancer. For example, the Centers for Disease Control and Prevention reported in June 2025 that the number of new lung cancer cases in the United States escalated from 218,893 in 2022 to 238,340 in 2023. Consequently, the soaring cases of lung cancer are propelling the ensartinib market growth. Access to progressive cancer treatments due to the surge in healthcare expenditure is another factor contributing to the ensartinib market's growth. The term 'healthcare expenditure' represents the aggregate amount spent by individuals, organizations, or governments on services like public health programs, medications, medical services, and other health-focused activities. With the aging population requiring more regular and specialized medical care, healthcare expenditure is seeing a surge. This increasing expenditure supports ensartinib usage by financing sophisticated cancer treatments and ensuring their availability in healthcare facilities. As per the data from the American Medical Association in April 2025, health spending in the U.S. increased by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person, which is a significant surge from the 4.6% growth seen in 2022. Therefore, the escalating healthcare expenditure fuels the growth of the ensartinib market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28213&type=smp

What Trends Will Shape the Ensartinib Market Through 2029 and Beyond?
Leading firms in the ensartinib market are strategizing to obtain needed regulatory approvals to expand patient availability in key world markets, and achieve label extensions for additional ALK-positive NSCLC uses. Regulatory approvals serve as the official green light from health bodies, confirming a drug, like ensartinib's safety, effectiveness, and quality before it's marketed and prescribed. For example, in December 2024, Xcovery Holdings, Inc., a biopharmaceutical firm based in the US, was granted FDA approval for selling ensartinib (under the brand name Ensacove) for the treatment of adult patients, who hadn't received an ALK inhibitor before, suffering from ALK-positive locally progressed or metastatic non-small cell lung cancer (NSCLC). This approval was arrived at after the Phase 3 eXALT3 trial, in which ensartinib demonstrated a notable increase in progression-free survival as compared to crizotinib (by a medium of 25.8 months vs 12.7 months), even though the overall survival was almost the same for both. Designed as a second-generation ALK inhibitor, ensartinib functions to surpass resistance and targets abnormal ALK proteins; its standard side effects comprise rash, muscle pain, constipation, cough, itchiness, nausea, swelling, fever, and fatigue.

What Are the Main Segments in the Ensartinib Market?
The ensartinib market covered in this report is segmented as

1) By Drug Type: Oral, Injectable
2) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
3) By Indication: Non-Small Cell Lung Cancer (NSCLC), Other Lung Cancers, Potential New Indications
4) By Treatment Line: First-Line Treatment, Second-Line Treatment, Third-Line And Beyond Treatment
5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:
1) By Oral: Capsules, Tablets, Liquid Formulations, Powder For Oral Suspension
2) By Injectable: Vials, Prefilled Syringes, Lyophilized Powder, Solution For Injection

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=28213&type=smp

Which Top Companies are Driving Growth in the Ensartinib Market?
Major companies operating in the ensartinib market are Xcovery Holdings Inc., Betta Pharmaceuticals Co. Ltd.

Which Regions Will Dominate the Ensartinib Market Through 2029?
North America was the largest region in the ensartinib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ensartinib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=28213

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.